Serum albumin and survival in glioblastoma multiforme

Borg, Nicholas; Guilfoyle, Mathew R.; Greenberg, David; Watts, Colin; Thomson, Simon

doi:10.1007/s11060-011-0562-0

Cited by 42 publications

(38 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Schwartzbaum et al found that preoperative hypoalbuminemia (<3.4 g/dL) was associated with a marked reduction in median survival from 494 to 62 days in 24 GBM patients . Several subsequent studies also identified preoperative serum albumin as a survival predictor for GBM . In our retrospective review, lower long‐term serum albumin level was independently associated with shorter survival after adjustment for the significant confounders.…”

Section: Discussionmentioning

confidence: 52%

The Association Between Common Clinical Characteristics and Postoperative Morbidity and Overall Survival in Patients with Glioblastoma

et al. 2018

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is one of the most feared cancer diagnoses because of its limited survival and treatment. This study revealed significant associations of noncancerous factors on the morbidity and mortality of GBM. The complexity of medical comorbidities, as well as short-term postoperative levels and fluctuations of blood pressure and blood glucose, was associated with postoperative complications, but not overall survival. However, long-term levels of these common clinical parameters were significantly associated with survival. Optimization of medical conditions may be critical for reducing the morbidity and mortality of GBM patients. Future clinical trials are needed to validate the observed associations in an independent cohort.

show abstract

Section: Discussionmentioning

confidence: 52%

The Association Between Common Clinical Characteristics and Postoperative Morbidity and Overall Survival in Patients with Glioblastoma

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Preoperative serum albumin levels have been recognized as prognostic in glioblastomas [8,9]. However, this prognostic effect should be re-examined in the era of standard therapy [1], when molecular markers such as MGMT promoter methylation status are taken into consideration [14,15].…”

Section: Discussionmentioning

confidence: 99%

“…In inflammatory conditions, high serum IGFBP-2 levels are associated with elevated cytokine interleukin (IL)-6 [22,24-26], another prognostic factor for glioblastoma [9,27] that negatively regulates serum albumin level by increasing catabolism and down-regulating hepatic synthesis, which further worsens the nutritional status of the patient. Therefore, during glioblastoma-induced inflammatory responses, the interaction among albumin, IGFBP-2 and IL-6 may greatly affect clinical outcomes.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, hypoalbuminemia is independently associated with poor survival in numerous solid cancers [7]. A relationship between serum albumin and survival in glioblastoma patients has also been reported [8,9]. However, the potential effects of standard therapy and the molecular marker O -methylguanine-DNA methyltransferase (MGMT) on the prognostic role of serum albumin remain unclear.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The prognostic role of preoperative serum albumin levels in glioblastoma patients

Han

Huang

et al. 2015

BMC Cancer

View full text Add to dashboard Cite

BackgroundSerum albumin level is a reliable and convenient marker of the nutritional status of patients, and has been identified as a prognostic marker in glioblastoma. However, because of the recent wide application of standard radio-chemotherapy for the treatment of glioblastoma patients, the prognostic effect of preoperative serum albumin levels needs to be re-evaluated and the related mechanism should be further explored.MethodsA total of 214 patients with histologically proven glioblastoma who underwent treatment at our institution between 2009 and 2012 were retrospectively analyzed. Clinical information was obtained from electronic medical records. Kaplan–Meier analysis and Cox proportional hazards models were used to examine the survival function of preoperative serum albumin levels in these glioblastoma patients.ResultsSerum albumin levels were significantly correlated with overall survival in glioblastoma patients (multivariate HR = 0.966; 95% CI, 0.938-0.995; P = 0.023). Serum albumin level was high in patients receiving standard therapy, which may affect its prognostic significance. Despite the correlation between serum albumin levels and other nutritional indicators such as prealbumin, total protein and total lymphocyte counts, only serum albumin level was an independent predictor of patient survival.ConclusionsSerum albumin level is associated with prognosis in glioblastoma patients, although the underlying mechanism is complex because of the role of serum albumin as a nutritional indicator and its involvement in inflammatory responses.

show abstract

“…Similarly, nutritional status and in ammation could re ect survival outcomes in high-grade gliomas 5 . Serum albumin level has been found to be an independent prognostic factor for survival, and lower albumin levels correlated with poor prognosis in patients with GBM [14][15][16] . Recent studies also showed the PNI to be an independent prognostic factor for survival in GBM [17][18][19][20][21] .…”

Section: Introductionmentioning

confidence: 99%

Impact of Prognostic Nutritional Index on Survival in Recurrent High-Grade Glial Tumors Treated with Systemic Treatment

Alan¹,

Telli²,

Başoğlu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Primary brain tumors are relatively rare malignancy, with high-grade gliomas (glioblastoma multiforme and anaplastic gliomas) are the most common types . We aimed to evaluate the prognostic value of Prognostic Nutritional Index (PNI), which is calculated by lymphocyte count and albumin, in recurrent high-grade glioma patients treated with systemic treatment.Methods: Data of 92 patients with recurrent high-grade glioma who received systemic treatment and followed in our clinic between 2012-2018 was retrospectively collected and analyzed. PNI was calculated as: [(10 × serum albumin (g/dL)) + (0.005 × total lymphocyte count)]. Patients were categorized according to the median PNI value. We investigated the prognostic role of PNI groups, and survival outcomes.Results: Median value of PNI was 46.02, and median follow-up duration was 9 months (1-68 months). Median overall survival (OS) was 8.1 months (95%CI: 6.04-10.3). Median OS was significantly longer in patients with PNI> 46.02 compared to patients with PNI ≤ 46.02 (13.9 months (95%CI: 9.8-18.1), and 6.07 months (95%CI: 4.3-7.7), p=0.01, respectively). In multivariate analysis, PNI was found to be an independent prognostic factor for OS [HR:0.54(95%CI:0.3-0.97), p=0.03)].Conclusion: In our study, the PNI was found to be an independent prognostic biomarker in patients with recurrent high-grade gliomas, but further prospective trials are necessary to validate its prognostic role.

show abstract

Serum albumin and survival in glioblastoma multiforme

Cited by 42 publications

References 27 publications

The Association Between Common Clinical Characteristics and Postoperative Morbidity and Overall Survival in Patients with Glioblastoma

The Association Between Common Clinical Characteristics and Postoperative Morbidity and Overall Survival in Patients with Glioblastoma

The prognostic role of preoperative serum albumin levels in glioblastoma patients

Impact of Prognostic Nutritional Index on Survival in Recurrent High-Grade Glial Tumors Treated with Systemic Treatment

Contact Info

Product

Resources

About